About 1% or fewer of the clinical trial participants reported suicidal thoughts or behaviors, with no differences between those taking semaglutide or a placebo, researchers reported Tuesday in the journal JAMA Internal Medicine
Quinn M, McMillin M, Galindo C, Frampton G, Pae HY, DeMorrow S
That creates a marketing opportunity: products can borrow the GLP-1 label and imply similar results, even when the product is not a prescription medication and does not contain a GLP-1 drug
Gaps between vials allow the medication to clear your system partially, which can lead to temporary return of appetite and other symptoms
The third is mixing CJC-1295 DAC and No DAC discussions as though they have the same duration
During your consultation, we will evaluate your medical history, lifestyle, and weight loss goals to determine the best treatment plan for you